BRCA1 and neoplasm: Furthermore, the ability to determine the mutational status of 170 cancer genes simultaneously provides insight into the co-occurrence patterns of mutations, additional oncogenic drivers, and intra- or inter-tumor heterogeneity, and is useful for identifying homologous recombination and DNA repair genes beyond BRCA1/2 which may be involved in the response to PARP inhibitors.